This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: MarketAxess, Domino's Pizza and Neurocrine Biosciences
by Zacks Equity Research
Zacks.com featured highlights include: MarketAxess, Domino's Pizza and Neurocrine Biosciences
3 Stocks With Momentum Anomaly to Buy This Earnings Season
by Zacks Equity Research
These frontrunners are currently witnessing a short-term pullback in price. So make sure you're taking full advantage of the opportunity.
MediWound (MDWD) Jumps: Stock Rises 9.4%
by Zacks Equity Research
MediWound (MDWD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: LLY, ABBV, NBIX and RDY
by Zacks Equity Research
The Zacks Analyst Blog Highlights: LLY, ABBV, NBIX and RDY
3 Stocks to Buy on New Drug Approvals by FDA
by Manaswita Ghosh Dutta
In May, the Food and Drug Administration approved as many as 13 new drugs, higher than the eight approved in the same month last year.
AbbVie Gets FDA Nod for Oriahnn to Control Menstrual Bleeding
by Zacks Equity Research
The FDA approves AbbVie's (ABBV) Oriahnn oral capsule for checking heavy menstrual bleeding related to uterine fibroids in pre-menopausal women. It will be sold in US markets by June-end.
Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of 46.43% and 8.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Neurocrine Biosciences (NBIX) This Earnings Season?
by Zacks Equity Research
Neurocrine Biosciences (NBIX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
COLL or NBIX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COLL vs. NBIX: Which Stock Is the Better Value Option?
COLL or NBIX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COLL vs. NBIX: Which Stock Is the Better Value Option?
Neurocrine Biosciences (NBIX) Q4 Earnings Lag Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -57.32% and 0.71%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Waters, Neurocrine Biosciences, Spirit Airlines, NuStar Energy and The RMR Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Waters, Neurocrine Biosciences, Spirit Airlines, NuStar Energy and The RMR Group
5 Top Stocks Set to Beat Earnings Estimates Next Week
by Nalak Das
Although, expectations for fourth-quarter 2019 earnings are negative at present, results so far are far better than initially anticipated.
Bet on Earnings Beat With 5 Top-Ranked Stocks
by Sanghamitra Saha
These top-ranked stocks are likely to beat on bottom line in their next releases.
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Zumiez, Neurocrine Biosciences and Covanta
by Zacks Equity Research
Zacks.com featured highlights include: Zumiez, Neurocrine Biosciences and Covanta
Look Beyond Earnings Growth, Tap the Beat With These 3 Stocks
by Sanghamitra Saha
Inside the top-ranked stocks that can beat earnings estimates in their next releases.
AMRX vs. NBIX: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMRX vs. NBIX: Which Stock Is the Better Value Option?
Will Neurocrine (NBIX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Neurocrine (NBIX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Breakout Stocks of the Last Decade to Consider for 2020
by Christopher Vargas
The 2010s were a fruitful decade for investors as the S&P 500 has surged over 189% so far.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Neurocrine Biosciences (NBIX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of 19.70% and 5.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?